2023 Was a troublesome yr for that biopharma industry, with many providers downsizing and restructuring their workforces to remain afloat. You'll find signs of recovery, as mergers and acquisitions picked up throughout the pharmaceutical and lifetime sciences marketplace during the latter part of 2023 and have continued their upswing into https://sites.google.com/view/bio-sites/blog